Felicitex Therapeutics Inc. (FLCT)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	44.73M
Revenue (ttm)	n/a
Net Income	-1.97M
EPS	-0.28
Shares Out	7.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About FLCT

Felicitex Therapeutics is a preclinical oncology drug development company focused on developing therapies targeting dormant and active cancer cells. We have designed and patented small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. This approach is lethal to cancer cells that rely on deregulation of the cell cycle for survival and has been shown to lead to the reversal of acquired resistance mechanisms. Our drug candidates are intended to be effective acr...

• Industry: Health Care
• Sector: Pharmaceuticals
• Founded: 2012
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: FLCT
• Website: https://www.felicitex.com/

Financial Performance

Data Source: SEC filings Last updated: Sep 4, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error